Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (OLMA)
CUSIP: 68062P106
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 87,489,196
- Total 13F shares
- 70,511,948
- Share change
- +4,985,239
- Total reported value
- $300,429,144
- Price per share
- $4.26
- Number of holders
- 120
- Value change
- +$22,565,282
- Number of buys
- 74
- Number of sells
- 54
Quarterly Holders Quick Answers
What is CUSIP 68062P106?
CUSIP 68062P106 identifies OLMA - Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 68062P106:
Top shareholders of OLMA - Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP |
3/4/5
13D/G
13F
|
10%+ Owner · Company |
10%
from 13D/G
|
13,407,200
|
$173,767,954 | — | 01 Aug 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
7.8%
|
6,843,954
|
$25,733,267 | — | 31 Mar 2025 | |
| BVF INC/IL |
13F
|
Company |
6.1%
|
5,295,893
|
$19,912,558 | — | 31 Mar 2025 | |
| Logos Global Management LP |
13D/G
13F
|
Company |
4.7%
|
3,208,875
|
$16,172,730 | $0 | 18 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
4.4%
|
3,822,342
|
$14,372,006 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
3.9%
|
3,442,833
|
$12,945,052 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
3.4%
|
3,011,969
|
$11,325,003 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
3.3%
|
2,930,446
|
$11,018,477 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.3%
|
2,871,613
|
$10,797,265 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
2.3%
|
1,543,931
|
$7,781,412 | $0 | 31 Mar 2025 | |
| Lightspeed Management Company, L.L.C. |
13F
|
Company |
2.2%
|
1,930,894
|
$7,260,161 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
2.1%
|
1,879,013
|
$7,065,089 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.1%
|
1,872,628
|
$7,041,081 | — | 31 Mar 2025 | |
| G. Walmsley Graham |
3/4/5
|
Director |
—
mixed-class rows
|
1,824,150
mixed-class rows
|
$5,724,000 | — | 11 Jun 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
1.7%
|
1,505,862
|
$5,662,041 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.7%
|
1,477,907
|
$5,556,930 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.7%
|
1,473,679
|
$5,541,034 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.5%
|
1,319,179
|
$4,961,914 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
1.3%
|
1,151,147
|
$4,328,313 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
1,083,126
|
$4,073,429 | — | 31 Mar 2025 | |
| BVF PARTNERS L P/IL |
3/4/5
|
Director, Other* |
—
mixed-class rows
|
807,964
mixed-class rows
|
$3,716,633 | — | 11 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.1%
|
978,848
|
$3,680,468 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1%
|
908,548
|
$3,416,141 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.99%
|
865,556
|
$3,254,491 | — | 31 Mar 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.97%
|
850,517
|
$3,197,982 | — | 31 Mar 2025 | |
| Pier Capital, LLC |
13F
|
Company |
0.93%
|
817,961
|
$3,075,533 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.85%
|
741,329
|
$2,787,398 | — | 31 Mar 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.61%
|
533,111
|
$2,191,086 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.52%
|
451,691
|
$1,698,357 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.48%
|
418,085
|
$1,571,999 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.46%
|
399,799
|
$1,503,245 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.42%
|
368,104
|
$1,384,071 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.4%
|
349,023
|
$1,312,326 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.39%
|
344,296
|
$1,294,553 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.37%
|
325,000
|
$1,222,000 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.37%
|
319,950
|
$1,203,011 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.33%
|
286,933
|
$1,078,868 | — | 31 Mar 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.28%
|
242,486
|
$911,747 | — | 31 Mar 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.24%
|
212,185
|
$797,816 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.22%
|
191,994
|
$721,897 | — | 31 Mar 2025 | |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC |
13F
|
Company |
0.2%
|
175,448
|
$659,684 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.17%
|
153,104
|
$575,670 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.16%
|
138,552
|
$520,956 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.16%
|
138,000
|
$518,880 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
131,994
|
$496,297 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.13%
|
113,018
|
$424,948 | — | 31 Mar 2025 | |
| Dana Investment Advisors, Inc. |
13F
|
Company |
0.13%
|
112,954
|
$424,707 | — | 31 Mar 2025 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.11%
|
100,000
|
$376,000 | — | 31 Mar 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.11%
|
93,669
|
$352,195 | — | 31 Mar 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.11%
|
92,310
|
$347,086 | — | 31 Mar 2025 |
Institutional Holders of Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (OLMA) as of Q2 2025
As of 30 Jun 2025,
Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (OLMA) was held by
120 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
70,511,948 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, Paradigm Biocapital Advisors LP, BVF INC/IL, BlackRock, Inc., Woodline Partners LP, Deep Track Capital, LP, VANGUARD GROUP INC, Logos Global Management LP, JANUS HENDERSON GROUP PLC, and FRANKLIN RESOURCES INC.
This page lists
121
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
131
Q2 2025 holders
120
Holder diff
-11
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.